COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00747227
Recruitment Status : Completed
First Posted : September 5, 2008
Results First Posted : November 11, 2011
Last Update Posted : November 11, 2011
Information provided by (Responsible Party):
Abbott Medical Optics

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (IOL).

Condition or disease Intervention/treatment Phase
Cataract Device: modified light transmission intraocular lens Device: monofocal acrylic intraocular lens Phase 3

Detailed Description:
The investigational IOL will be found to be safe and effective with respect to visual acuity, color vision, contrast sensitivity and complications and will be similar to results for the ZA9003 control eyes. Complication rates and adverse event rates will be within the FDA grid for posterior chamber IOLs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of a Modified Light Transmission IOL
Study Start Date : December 2006
Actual Primary Completion Date : March 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: ZV9003
modified light transmission intraocular lens
Device: modified light transmission intraocular lens
violet visible light blocking acrylic intraocular lens
Other Name: ZV9003

Active Comparator: ZA9003
monofocal acrylic intraocular lens
Device: monofocal acrylic intraocular lens
conventional hydrophobic acrylic intraocular lens
Other Name: ZA9003

Primary Outcome Measures :
  1. Best Corrected Distance Visual Acuity [ Time Frame: One year ]
    Snellen Equivalent visual acuity of 20/40 or better

  2. Uncorrected Distance Visual Acuity [ Time Frame: One Year ]
    Snellen Equivalent of 20/40 or better at one year

Secondary Outcome Measures :
  1. Contrast Sensitivity [ Time Frame: 4-6 months ]
    Contrast sensitivity is the measurement of how faded an image may become before it can clearly be seen. Contrast sensitivity was measured in photopic and mesopic conditions at the following spatial frequencies: 3.0, 6.0, 12.0, and 18 cpd (cycles per degree). Contrast sensitivity is measured in log units. A higher value for the logarithmic units translates to better contrast sensitivity.

  2. Subject Satisfaction - Subjects Satisfied With Overall Eyesight Rated as "Good" or "Excellent". [ Time Frame: One Year ]
    Subjects indicating a subjective response to a multiple choice question, "At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?", on a multi-item questionnaire administered by interviewer to determine subject satisfaction with their overall visual outcome at the one year visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 years of age or older
  • Bilateral cataracts for which phacoemulsification extraction and posterior IOL implantation has been planned
  • Visual potential in both eyes of 20/30 Snellen or better after cataract removal and IOL implantation
  • Preoperative corneal astigmatism of 1.5 diopters or less

Exclusion Criteria:

  • Use of systemic or ocular medications that may affect vision
  • Uncontrolled systemic or recurrent ocular disease
  • Requiring an intraocular lens <15.0 or >26.0 diopters
  • Abnormal results with the Farnsworth-Munsell D-15 and/or Ishihara color plates
  • History of ocular trauma or prior ocular surgery
  • Known pathology that may affect visual acuity or visual field
  • Corneal abnormalities
  • Pupil abnormalities
  • Capsule or zonular abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00747227

Layout table for location information
United States, Arizona
Patrick Aiello, M.D.
Scottsdale, Arizona, United States, 85054
United States, Arkansas
Randall E. Cole, M.D.
Rogers, Arkansas, United States, 72756
United States, Connecticut
Aron Rose, M.D.
New Haven, Connecticut, United States, 06510
United States, Minnesota
Y. Ralph Chu, M.D.
Bloomington, Minnesota, United States, 55420
United States, Missouri
Steven Silverstein, M.D.
Kansas City, Missouri, United States, 64133
United States, Oregon
Jon-Marc Weston, M.D.
Roseburg, Oregon, United States, 97470
United States, Pennsylvania
William Christie, M.D.
Cranberry Township, Pennsylvania, United States, 16066
Mark Blecher, M.D.
Philadelphia, Pennsylvania, United States, 19148
United States, Rhode Island
Robert L. Bahr, M.D.
Providence, Rhode Island, United States, 02906
United States, South Dakota
Vance Thompson, M.D.
Sioux Falls, South Dakota, United States, 57105
United States, Washington
Jay Rudd, M.D.
Lacey, Washington, United States, 98503
Sponsors and Collaborators
Abbott Medical Optics
Layout table for investigator information
Principal Investigator: Roger F. Steinert, M.D. University of California, Irvine, Dept. of Ophthalmology
Layout table for additonal information
Responsible Party: Abbott Medical Optics Identifier: NCT00747227    
Other Study ID Numbers: BBLK-102-PRSM
First Posted: September 5, 2008    Key Record Dates
Results First Posted: November 11, 2011
Last Update Posted: November 11, 2011
Last Verified: October 2011
Keywords provided by Abbott Medical Optics:
intraocular lens
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Eye Diseases